[Pharmacodynamic examples on the effect enhancement or alteration of action through molecular dimerization].
D000109:Acetylcholine / Q000494:pharmacology; D000818:Animals; D001665:Binding Sites; D002217:Carbachol / Q000494:pharmacology; D002802:Cholinesterases / Q000097:blood; D003326:Coronary Circulation / Q000187:drug effects; D003998:Dicarboxylic Acids / Q000494:pharmacology; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D004912:Erythrocytes / Q000201:enzymology; D006321:Heart / Q000187:drug effects; D006592:Hexobendine / Q000494:pharmacology; D006594:Hexoprenaline / Q000494:pharmacology; D006801:Humans; D007545:Isoproterenol / Q000494:pharmacology; D009206:Myocardium / Q000378:metabolism; D009388:Neostigmine / Q000494:pharmacology; D009466:Neuromuscular Blocking Agents / Q000494:pharmacology; D013329:Structure-Activity Relationship; D013390:Succinylcholine / Q000494:pharmacology; D009435:Synaptic Transmission / Q000187:drug effects
D003998:Dicarboxylic Acids; D009466:Neuromuscular Blocking Agents; D009388:Neostigmine; D002217:Carbachol; D006592:Hexobendine; D002802:Cholinesterases; D006594:Hexoprenaline; D013390:Succinylcholine; D007545:Isoproterenol; D000109:Acetylcholine
Pharmakodynamische Beispiele der Wirkungsverstärking bzw. -änderung durch Molekülverdopplung